Levosimendan: A FDA-Approved Drug Treating Heart Failure Also Blocks HIV-1 Reactivation
Share This:
                           

About The Author

Dr. Jian Zhu is an associate professor at OSU in the Department of Pathology. He studies the host-virus interactions, particularly for HIV and herpesviruses, by using multidisciplinary "state-of-the-art" systematic approaches towards the better understanding of viral pathogenesis, antiviral defense mechanisms, and their consequences in critical diseases, such as cancer and autoimmunity

                       

Levosimendan: A FDA-Approved Drug Treating Heart Failure Also Blocks HIV-1 Reactivation

Human immunodeficiency virus type 1 (HIV-1) infection causes acquired immune deficiency syndrome (AIDS), which remains a major public health concern. Combination antiretroviral therapy (cART), typically consisting three or more antiretroviral drugs, has been shown to efficiently block active HIV-1 replication, which leads to an improved life expectancy of HIV-infected patients. Nevertheless, HIV-1/AIDS is still an incurable disease, because cART is unable to completely eliminate HIV-1 due to the presence of HIV-1 latent reservoir being resistant to antiretroviral drugs. Activated CD4+ T...

Read more